Real world utilization of the myositis autoantibody panel.
Mithu MaheswaranathanAndrew JohannemannJason J WeinerRyan JesseeAmanda M EudyLisa Criscione-SchreiberPublished in: Clinical rheumatology (2021)
• Only eighteen percent of all myositis antibody panel tests ordered returned positive. • Anti-Mi-2 antibody was the most frequent autoantibody in our cohort. • Specific factors associated with positive results can help identify patients at higher risk for IIM, particularly for non-rheumatologists.